Clopidogrel in acute coronary syndrome: Implications of recent study findings

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 9, 2010, Pages 1215-1229

  Duerschmied, Daniel ^a   Bode, Christoph ^a   Moser, Martin ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

acute coronary syndrome; antiplatelet therapy; clopidogrel; P2Y12 inhibitor; thienopyridine

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ACETYLSALICYLIC ACID; APD 791; APTAMER; ARC 1779; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; E 5555; FIBRINOGEN; FIBRINOGEN RECEPTOR; OMEPRAZOLE; PANTOPRAZOLE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PRASUGREL; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; RABEPRAZOLE; SARPOGRELATE; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST; TERUTROBAN; THROMBIN RECEPTOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; TICAGRELOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; BLEEDING TENDENCY; BONE MARROW TOXICITY; BRAIN HEMORRHAGE; CLINICAL TRIAL; CORONARY STENT; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG METABOLISM; DYSPEPSIA; FEVER; HUMAN; LOW DRUG DOSE; NEUTROPENIA; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PHARMACOGENETICS; PURPURA; RASH; RECOMMENDED DRUG DOSE; REVIEW; STENT THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; HUMANS; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE;

EID: 77956547060     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.104     Document Type: Review

References (125)

1. Lerberghe WV, Evans T, Rasanathan K, Mechbal A. The World Health Report 2008: Primary Health Care Now More Than Ever. WHO, Geneva, Switzerland (2008).
2. Davi G, Patrono C. Platelet activation and atherothrombosis. N. Engl. J. Med. 357(24), 2482-2494 (2007).
3. Bassand JP, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 28(13), 1598-1660 (2007).
4. Kushner FG, Hand M, Smith SC Jr. et al. 2009 Focused Updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 120(22), 2271-2306 (2009).
5. Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116(7), e148-e304 (2007).
6. 12 inhibitors: thienopyridines and direct oral inhibitors. Hamostaseologie 29(4), 339-348 (2009).
7. Denis CV, Wagner DD. Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler. Thromb. Vasc. Biol. 27(4), 728-739 (2007).
8. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fbrinogen or translocation on von Willebrand factor. Cell 84(2), 289-297 (1996).
9. Reininger AJ, Bernlochner I, Penz SM et al. A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. J. Am. Coll. Cardiol. 55(11), 1147-1158 (2010).
10. Bergmeier W, Piffath CL, Goerge T et al. The role of platelet adhesion receptor GPIba far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc. Natl Acad. Sci. USA 103(45), 16900-16905 (2006).
11. Nieswandt B, Brakebusch C, Bergmeier W et al. Glycoprotein VI but not a2b1 integrin is essential for platelet interaction with collagen. EMBO J. 20(9), 2120-2130 (2001).
12. Nesbitt WS, Westein E, Tovar-Lopez FJ et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat. Med. 15(6), 665-673 (2009).
13. Ruggeri ZM, Orje JN, Habermann R, Federici AB, Reininger AJ. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood 108(6), 1903-1910 (2006).
14. Gurbel PA, Tantry US. Combination antithrombotic therapies. Circulation 121(4), 569-583 (2010).
15. Raju NC, Eikelboom JW, Hirsh J. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat. Clin. Pract. Cardiovasc. Med. 5(12), 766-780 (2008).
16. Stefanini L, Roden RC, Bergmeier W CalDAG-GEFI is at the nexus of calcium-dependent platelet activation. Blood 114(12), 2506-2514 (2009).
17. Cifuni SM, Wagner DD, Bergmeier W CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin aIIbb3 in platelets. Blood 112(5), 1696-1703 (2008).
18. Crittenden JR, Bergmeier W, Zhang Y et al. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat. Med. 10(9), 982-986 (2004).
19. Chrzanowska-Wodnicka M, Smyth SS, Schoenwaelder SM, Fischer TH, White GC 2nd. Rap1b is required for normal platelet function and hemostasis in mice. J. Clin. Invest. 115(3), 680-687 (2005).
20. McNicol A, Israels SJ. Platelet dense granules: structure, function and implications for haemostasis. Thromb. Res. 95(1), 1-18 (1999).
21. Gachet C, Leon C, Hechler B. The platelet P2 receptors in arterial thrombosis. Blood Cells Mol. Dis. 36(2), 223-227 (2006).
22. Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J. Biol. Chem. 273(4), 2030-2034 (1998).
23. Leon C, Hechler B, Freund M et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J. Clin. Invest. 104(12), 1731-1737 (1999).
24. Kauffenstein G, Bergmeier W, Eckly A et al. The P2Y() receptor induces 12 platelet aggregation through weak activation of the a (IIb) b(3) integrin-a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett. 505(2), 281-290 (2001).
25. Herbert JM, Savi P. P2Y, a new platelet 12 ADP receptor, target of clopidogrel. Semin. Vasc. Med. 3(2), 113-122 (2003).
26. CAPRIE-Steering-Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348(9038), 1329-1339 (1996).
27. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl J. Med. 345(7), 494-502 (2001).
28. Chen ZM, Jiang LX, Chen YP et al Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366(9497), 1607-1621 (2005).
29. Bhatt DL, Fox KA, Hacke W et al Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354(16), 1706-1717 (2006).
30. Bennett CL, Kim B, Zakarija A et al Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J. Am. Coll. Cardiol 50(12), 1138-1143 (2007).
31. Wallentin L. P2Y(+) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur. Heart J. 30(16), 1964-1977 (2009).
32. 14C-labeled clopidogrel. Semin. Thromb. Hemost. 25(Suppl. 2), 29-33 (1999).
33. Rehmel JL, Eckstein JA, Farid NA et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab. Dispos. 34(4), 600-607 (2006).
34. Kuliczkowski W, Witkowski A, Polonski L et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur. Heart J. 30(4), 426-435 (2009).
35. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107(23), 2908-2913 (2003).
36. Wiviott SD, Trenk D, Frelinger AL et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116(25), 2923-2932 (2007).
37. 12 receptor-mediated platelet inhibition than clopidogrel due to more effcient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur. Heart J. 29(1), 21-30 (2008).
38. 12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 50(19), 1852-1856 (2007).
39. Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360(4), 363-375 (2009).
40. Mega JL, Close SL, Wiviott SD et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354-362 (2009).
41. Collet JP, Hulot JS, Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373(9660), 309-317 (2009).
42. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical signifcance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41(12), 913-958 (2002).
43. Varenhorst C, James S, Erlinge D et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur. Heart J. 30(14), 1744-1752 (2009).
44. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, writing on behalf of the 2005 Writing Committee. Circulation 117(2), 261-295 (2008).
45. McColl KE, Kennerley P. Proton pump inhibitors-differences emerge in hepatic metabolism. Dig. Liver Dis. 34(7), 461-467 (2002).
46. Gilard M, Arnaud B, Cornily JC et al. Infuence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J. Am. Coll. Cardiol. 51(3), 256-260 (2008).
47. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180(7), 713-718 (2009).
48. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol. Ther. 31(8), 810-823 (2010).
49. O'Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical effcacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374(9694), 989-997 (2009).
50. Caplain H, D'Honneur G, Cariou R. Prolonged heparin administration during clopidogrel treatment in healthy subjects. Semin. Thromb. Hemost. 25(Suppl. 2), 61-64 (1999).
51. Eikelboom JW, Hankey GJ, Thom J et al. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. J. Thromb. Haemost. 3(12), 2649-2655 (2005).
52. Ufer M. Comparative effcacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb. Haemost. 103(3), 572-585 (2010).
53. Sibbing D, von Beckerath N, Morath T et al. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur. Heart J. 31(10), 1205-1211 (2010).
54. Neubauer H, Mugge A. Thienopyridines and statins: assessing a potential drug-drug interaction. Curr. Pharm. Des. 12(10), 1271-1280 (2006).
55. Gremmel T, Steiner S, Seidinger D et al. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart 96(3), 186-189 (2010).
56. 12 expressing leukocytes. Basic Res. Cardiol. 105(3), 379-387 (2010).
57. Bonello-Palot N, Armero S, Paganelli F et al. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am. J. Cardiol. 104(11), 1511-1515 (2009).
58. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet function profles in patients with Type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54(8), 2430-2435 (2005).
59. Geisler T, Grass D, Bigalke B et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J. Thromb. Haemost. 6(1), 54-61 (2008).
60. Neubauer H, Kruger JC, Lask S et al. Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. Clin. Res. Cardiol. 98(9), 533-540 (2009).
61. Kim SD, Kang W, Lee HW et al. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. Clin. Ther. 31(4), 793-803 (2009).
62. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102(6), 624-629 (2000).
63. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358(9281), 527-533 (2001).
64. Sabatine MS, Cannon CP, Gibson CM et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fbrinolytics: the PCI-CLARITY study. JAMA 294(10), 1224-1232 (2005).
65. Dasgupta A, Steinhubl SR, Bhatt DL et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am. J. Cardiol. 103(10), 1359-1363 (2009).
66. Berger JS, Bhatt DL, Cannon CP et al. The relative effcacy and safety of clopidogrel in women and men a sex-specifc collaborative meta-analysis. J. Am. Coll. Cardiol. 54(21), 1935-1945 (2009).
67. Ahrens I, Bode C. Novel antiplatelet therapies following percutaneous coronary interventions. Curr. Opin. Investig. Drugs 10(9), 902-911 (2009).
68. Kimura T, Morimoto T, Nakagawa Y et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 119(7), 987-995 (2009).
69. Airoldi F, Colombo A, Morici N et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116(7), 745-754 (2007).
70. Park SJ, Park DW, Kim YH et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N. Engl. J. Med. 362(15), 1374-1382 (2010).
71. Von Beckerath N, Taubert D, Pogatsa-Murray G et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 112(19), 2946-2950 (2005).
72. Angiolillo DJ, Costa MA, Shoemaker SB et al. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Am. J. Cardiol. 101(4), 440-445 (2008).
73. Aleil B, Jacquemin L, De Poli F et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc. Interv. 1(6), 631-638 (2008).
74. Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and infuence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb. Res. 121(4), 463-468 (2008).
75. Angiolillo DJ, Shoemaker SB, Desai B et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115(6), 708-716 (2007).
76. Mehta SR, Bassand JP, Chrolavicius S et al Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am. Heart J. 156(6), 1080-1088.e1 (2008).
77. Mehta SR. CURRENT-OASIS 7: a 2×2 factorial, randomized, trial of optimal clopidogrel and aspirin dosing in patients with ACS undergoing an early invasive strategy with intent for PCI. Presented at: European Society of Cardiology 2009 Congress. Barcelona, Spain, 30 August-2 September 2009
78. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 324(7329), 71-86 (2002).
79. Peters RJ, Mehta SR, Fox KA et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study. Circulation 108(14), 1682-1687 (2003).
80. Fox KA, Steg PG, Eagle KA et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 297(17), 1892-1900 (2007).
81. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001-2015 (2007).
82. Wiviott SD, Braunwald E, Angiolillo DJ et al. Greater clinical beneft of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 118(16), 1626-1636 (2008).
83. Montalescot G, Wiviott SD, Braunwald E et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373(9665), 723-731 (2009).
84. Gurbel PA, Bliden KP, Butler K et al. Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies. The RESPOND Study. Circulation 121(10), 1188-1199 (2010).
85. Cannon CP, Harrington RA, James S et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 375 (9711), 283-293 (2010).
86. Bhatt DL, Lincoff AM, Gibson CM et al Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med. 361(24), 2330-2341 (2009).
87. Harrington RA, Stone GW, McNulty S et al. Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med. 361(24), 2318-2329 (2009).
88. Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler. Suppl. 6(4), 3-11 (2005).
89. Jeong YH, Hwang JY, Kim IS et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ. Cardiovasc. Interv. 3(1), 17-26 (2010).
90. Jeong YH, Lee SW, Choi BR et al Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J. Am. Coll Cardiol. 53(13), 1101-1109 (2009).
91. Chen KY, Rha SW, Li YJ et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 119(25), 3207-3214 (2009).
92. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367(9523), 1665-1673 (2006).
93. Walther DJ, Peter JU, Winter S et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet a-granule release. Cell 115(7), 851-862 (2003).
94. Duerschmied D, Bode C. The role of serotonin in haemostasis. Hamostaseologie 29(4), 356-359 (2009).
95. Golino P, Piscione F, Willerson JT et al. Divergent effects of serotonin on coronary-artery dimensions and blood fow in patients with coronary atherosclerosis and control patients. N. Engl. J. Med. 324(10), 641-648 (1991).
96. Duerschmied D, Canault M, Lievens D et al. Serotonin stimulates platelet receptor shedding by tumor necrosis factor-a-converting enzyme (ADAM17). J. Thromb. Haemost. 7(7), 1163-1171 (2009).
97. Adams JW, Ramirez J, Shi Y et al. APD791, 3-methoxy-N-(3-(1-methyl-1H- pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl) benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profle, pharmacokinetics, platelet activity and vascular biology. J. Pharmacol. Exp. Ther. 331(1), 96-103 (2009).
98. Przyklenk K, Frelinger AL 3rd, Linden MD et al. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J. Thromb. Haemost. 8(2), 331-340 (2010).
99. Nishihira K, Yamashita A, Tanaka N et al. Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery. J. Thromb. Haemost. 4(1), 247-255 (2006).
100. Fujita M, Mizuno K, Ho M et al. Sarpogrelate treatment reduces restenosis after coronary stenting. Am. Heart J. 145(3), E16 (2003).
101. Shinohara Y, Nishimaru K, Sawada T et al. Sarpogrelate-Aspirin Comparative Clinical Study for Effcacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): a randomized, double-blind, aspirin-controlled trial. Stroke 39(6), 1827-1833 (2008).
102. Diener JL, Daniel Lagasse HA, Duerschmied D et al. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J. Thromb. Haemost. 7(7), 1155-1162 (2009).
103. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 116(23), 2678-2686 (2007).
104. Spiel AO, Mayr FB, Ladani N et al. The aptamer ARC1779 is a potent and specifc inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction. Platelets 20(5), 334-340 (2009).
105. Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic, pharmacodynamic and clinical profle of novel antiplatelet drugs targeting vascular diseases. Br. J. Pharmacol. 159(3), 502-517 (2009).
106. Vilahur G, Casani L, Badimon L. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic effcacy in an experimental model of stent-induced thrombosis. Thromb. Haemost. 98(3), 662-669 (2007).
107. Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin. Thromb. Hemost. 35(2), 158-167 (2009).
108. Lages B, Weiss HJ. Biphasic aggregation responses to ADP and epinephrine in some storage pool defcient platelets: relationship to the role of endogenous ADP in platelet aggregation and secretion. Thromb. Haemost. 43(2), 147-153 (1980).
109. Marcucci R, Gori AM, Paniccia R et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119(2), 237-242 (2009).
110. Sibbing D, Braun S, Morath T et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 53(10), 849-856 (2009).
111. Mueller T, Dieplinger B, Poelz W, Calatzis A, Haltmayer M. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer-comparison with two fow cytometric methods. Thromb. Res. 121(2), 249-258 (2007).
112. 12) expressing leukocytes. Basic Res. Cardiol. 105(3), 379-387 (2010).
113. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 110(19), e489-e493 (2004).
114. Minamino T, Kitakaze M, Sanada S et al. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fbrillation: role of nitric oxide. Circulation 98(17), 1721-1727 (1998).
115. Aleil B, Ravanat C, Cazenave JP et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J. Thromb. Haemost. 3(1), 85-92 (2005).
116. Tantry US, Bliden K P, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J. Am. Coll. Cardiol. 46(9), 1705-1709 (2005).
117. Breet NJ, van Werkum JW, Bouman HJ et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303(8), 754-762 (2010).
118. Hochholzer W, Trenk D, Bestehorn HP et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J. Am. Coll. Cardiol. 48(9), 1742-1750 (2006).
119. Sibbing D, Braun S, Jawansky S et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb. Haemost. 99(1), 121-126 (2008).
120. Siller-Matula JM, Christ G, Lang IM et al. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J. Thromb. Haemost. 8(2), 351-359 (2010).
121. 12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1. Cell Calcium 35(1), 39-46 (2004).
122. Madsen EH, Saw J, Kristensen SR et al. Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, Verify Now, and thrombelastography in patients undergoing percutaneous coronary intervention. Clin. Chem. 56(5), 839-847 (2010).
123. Barragan P, Bouvier JL, Roquebert PO et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter. Cardiovasc. Interv. 59(3), 295-302 (2003).
124. Frere C, Cuisset T, Quilici J et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb. Haemost. 98(4), 838-843 (2007).
125. Bonello L, Camoin-Jau L, Arques S et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol. 51(14), 1404-1411 (2008).